TY - JOUR T1 - Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. AU - ,, AU - Nicolucci,A, AU - Maione,A, AU - Franciosi,M, AU - Amoretti,R, AU - Busetto,E, AU - Capani,F, AU - Bruttomesso,D, AU - Di Bartolo,P, AU - Girelli,A, AU - Leonetti,F, AU - Morviducci,L, AU - Ponzi,P, AU - Vitacolonna,E, Y1 - 2008/01/14/ PY - 2008/1/19/pubmed PY - 2008/4/12/medline PY - 2008/1/19/entrez SP - 213 EP - 20 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet Med VL - 25 IS - 2 N2 - AIMS: The aim of this case-control study was to compare quality of life (QoL) and treatment satisfaction in adults with Type 1 diabetes (T1DM) treated with either continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI). METHODS: Consecutive patients aged between 18 and 55 years, and attending diabetes clinics for a routine visit, completed the Diabetes-Specific Quality-of-Life Scale (DSQOLS), the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the SF-36 Health Survey (SF-36). Case (CSII) and control subjects (MDI) were recruited in a 1 : 2 ratio. RESULTS: Overall, 1341 individuals were enrolled by 62 diabetes clinics; 481 were cases and 860 control subjects. Cases had a longer diabetes duration and were more likely to have eye and renal complications. Age, school education, occupation and HbA(1c) were similar. Of control subjects, 90% followed glargine-based MDI regimens and 10% used NPH-based MDI regimens. On multivariate analysis, after adjusting for socioeconomic and clinical characteristics, scores in the following areas of the DSQOLS were higher in cases than control subjects: diet restrictions (beta = 5.96; P < 0.0001), daily hassles (beta = 3.57; P = 0.01) and fears about hypoglycaemia (beta = 3.88; P = 0.006). Treatment with CSII was also associated with a markedly higher DTSQ score (beta = 4.13; P < 0.0001) compared with MDI. Results were similar when CSII was compared separately with glargine- or NPH-based MDI regimens. CONCLUSIONS: This large, non-randomized, case-control study suggests quality of life gains deriving from greater lifestyle flexibility, less fear of hypoglycaemia, and higher treatment satisfaction, when CSII is compared with either glargine-based or NPH-based MDI regimens. SN - 1464-5491 UR - https://www.unboundmedicine.com/medline/citation/18201210/Quality_of_life_and_treatment_satisfaction_in_adults_with_Type_1_diabetes:_a_comparison_between_continuous_subcutaneous_insulin_infusion_and_multiple_daily_injections_ DB - PRIME DP - Unbound Medicine ER -